Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

被引：0
|
作者：
Landgren, Ola
Alsina, Melissa
Biran, Noa
Vesole, David H.
Wallace, Paul K.
Fang, Belle
Arnold, Gregory
Kimball, Amy
Siegel, David S.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133803
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly
    Leleu, Xavier
    Chari, Ajai
    Richard, Shambavi
    Khurana, Monica
    Yusuf, Akeem
    Usmani, Saad Z.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (12) : 1049 - 1058
  • [32] A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Chanan-Khan, A.
    Roberts, A. W.
    Agarwal, A. B.
    Facon, T.
    Kumar, S.
    Touzeau, C.
    Cordero, J.
    Ross, J.
    Munasinghe, W.
    Jia, J.
    Salem, A. H.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Harrison, S. J.
    HAEMATOLOGICA, 2017, 102 : 169 - 169
  • [33] A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Cordero, Jaclyn
    Ross, Jeremy
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo
    Verdugo, Maria
    Harrison, Simon J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E16
  • [34] Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
    Gasparetto, Cristina
    Lipe, Brea
    Tuchman, Sascha
    Callander, Natalie Scott
    Lentzsch, Suzanne
    Baljevic, Muhamed
    Rossi, Adriana C.
    Bahlis, Nizar J.
    White, Darell
    Chen, Christine
    Sutherland, Heather J.
    Kotb, Rami
    LeBlanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Bensinger, William
    Sheehan, Heidi
    Ju, Yawen
    Kai, Kazuharu
    Schiller, Gary J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study ARROW
    Mateos, Maria-Victoria
    Moreau, Philippe
    Berenson, James R.
    Weisel, Katja
    Lazzaro, Antonio
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Huang, Mei
    Zahlten-Kumeli, Anita
    Stewart, A. Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Totani, Haruhito
    Ri, Masaki
    Kato, Chie
    Nakashima, Takahiro
    Suzuki, Nana
    Hagiwara, Shinya
    Kanamori, Takashi
    Murakami, Satsuki
    Masuda, Arisa
    Kinoshita, Shiori
    Yoshida, Takashi
    Narita, Tomoko
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (03) : 316 - 321
  • [37] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Haruhito Totani
    Masaki Ri
    Chie Kato
    Takahiro Nakashima
    Nana Suzuki
    Shinya Hagiwara
    Takashi Kanamori
    Satsuki Murakami
    Arisa Masuda
    Shiori Kinoshita
    Takashi Yoshida
    Tomoko Narita
    Asahi Ito
    Shigeru Kusumoto
    Takashi Ishida
    Hirokazu Komatsu
    Shinsuke Iida
    International Journal of Hematology, 2016, 103 : 316 - 321
  • [38] A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Gasparetto, Cristina
    Schiller, Gary J.
    Callander, Natalie Scott
    Lentzsch, Suzanne
    Tuchman, Sascha A.
    Bahlis, Nizar
    White, Darrell J.
    Chen, Christine I.
    Sutherland, Heather J.
    Baljevic, Muhamed
    Kotb, Rami
    Leblanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Bensinger, William I.
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Lipe, Brea C.
    BLOOD, 2019, 134
  • [39] Efficacy and Safety of Once-Weekly Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Secondary Analysis from the CHAMPION-1 Study by Prior Lines of Therapy
    Berdeja, Jesus
    Rifkin, Robert
    Lyons, Roger
    Cartmell, Alan
    Coleman, Morton
    Yang, Hui
    Zahlten-Kumeli, Anita
    Iskander, Karim
    Berenson, James
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E58 - E59
  • [40] ARROW2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    Dimopoulos, Meletios A.
    Coriu, Daniel
    Delimpasi, Sosana
    Spicka, Ivan
    Upchurch, Terry
    Fang, Belle
    Talpur, Rakhshandra
    Faber, Edward
    Beksac, Meral
    Leleu, Xavier
    BLOOD ADVANCES, 2024, 8 (19) : 5012 - 5021
12345